TORONTO, Sept. 12 /CNW/ - NeuroMedix Inc. ("NeuroMedix") (TSXV: NMX)
today announced that it has completed maximum tolerated dose ("MTD") studies
in two species of animals for Minozac, its lead drug candidate for the
treatment of Alzheimer's disease. The MTD studies were completed in two
species of animal and have defined the MTD of the compound based on oral
dosing to be in excess of 40 times the therapeutic dose used in a mouse model
of Alzheimer's disease.
